Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07110454 · ClinicalTrials.gov registry record
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
A clinical trial of Epilepsy and Epilepsy (Treatment Refractory), sponsored by Epiminder America.
- Recruiting
- Registry status
- 210
- Enrollment target
- 7
- Study locations
NCT07110454: Recruiting study of Epilepsy and Epilepsy (Treatment Refractory), sponsored by Epiminder America.
NCT07110454 is a study of Epilepsy and Epilepsy (Treatment Refractory) that is actively recruiting participants, run by Epiminder America. The registered enrollment target is 210 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07110454, a study of Epilepsy and Epilepsy (Treatment Refractory), is actively recruiting participants, sponsored by Epiminder America.
- RECRUITING
- Registry status
- 210 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research is being done to understand how the Minder System helps physicians make decisions about participant's epilepsy treatment after an actionable event. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational. Participants that have completed the DETECT study and received the Minder System previously will consent to join this long-term follow-up observational study. The study will collect information about general wellbeing, use of healthcare services, and experience using the Minder data over time to support long-term epilepsy care. All participants will continue to be followed by their treating physician and undergo assessments and visits every six (6) months until two (2) years after receiving the Minder device.
Conditions Studied
Interventions
- DEVICE Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
Study Locations (7)
Arizona
- Mayo Clinic - Arizona - Phoenix
Connecticut
- Yale School of Medicine - New Haven
Florida
- Mayo Clinic - Florida - Jacksonville
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
Missouri
- Washington University - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-01 |
What NCT07110454 shows while recruiting
NCT07110454 is an observational study that tracks outcomes without assigning an intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) is the first listed.
NCT07110454 lists 7 locations in 7 states (Arizona, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT07110454 about?
NCT07110454 is a clinical study titled "Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up". The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This...
What is the current status of trial NCT07110454?
This trial is currently recruiting. The enrollment target is 210 participants. The study started on 2026-06. Estimated completion is 2029-01.
What conditions does trial NCT07110454 study?
This clinical trial studies the following conditions: Epilepsy, Epilepsy (Treatment Refractory).
What interventions are being tested in trial NCT07110454?
The interventions under investigation include: Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) (DEVICE).
Who is sponsoring clinical trial NCT07110454?
This trial is sponsored by Epiminder America, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07110454 being conducted?
This trial has 7 study locations across Arizona, Connecticut, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07110454's enrollment target sits among peer trials
210 28th of 160 higher than 133 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia